Ticker

Shares of Atossa Genetics Inc. (NASDAQ: ATOS - Get Free Report) have earned a consensus recommendation of "Hold" from the five research firms that are currently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, two have given a buy recommendation and one has assigned a strong buy recommendation

Atossa Genetics Inc. (NASDAQ: ATOS - Get Free Report) saw a large growth in short interest during the month of January. As of January 30th, there was short interest totaling 4,696,759 shares, a growth of 29.7% from the January 15th total of 3,621,023 shares. Approximately 60.2% of the shares of the stock are sold short. Based

SEATTLE, Feb. 11, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet need, today issued a letter to Shareholders from Steven Quay, M.D., Ph.D., Atossa Therapeutics President and Chief Executive Officer, providing an update on the Company's clinical programs and…

Atossa's Rare Pediatric Disease Designation for (Z)-endoxifen in neuromuscular diseases qualifies for a future PRV upon FDA approval SEATTLE, Feb. 5, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today reaffirmed its strong market position around…

Atossa Genetics Inc. (NASDAQ: ATOS)'s stock is scheduled to reverse split before the market opens on Monday, February 2nd. The 1-15 reverse split was announced on Monday, January 26th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, January 30th. Atossa Genetics Trading Down 10.0% Shares